BIOMARIN PHARMACEUTICAL INCBMRNEarnings & Financial Report
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
BMRN Q4 2025 Key Financial Metrics
营收
$874.6M
毛利润
$598.9M
营业利润
$-44.6M
净利润
$-46.6M
毛利率
68.5%
营业利润率
-5.1%
净利率
-5.3%
同比增长
17.0%
EPS
$-0.22
资金流向
BIOMARIN PHARMACEUTICAL INC Q4 2025 Financial Summary
BIOMARIN PHARMACEUTICAL INC reported revenue of $874.6M (up 17.0% YoY) for Q4 2025, with a net profit of $-46.6M (down 137.3% YoY) (-5.3% margin). Cost of goods sold was $275.7M, operating expenses totaled $643.5M.
Key Financial Metrics
| Total Revenue | $874.6M |
|---|---|
| Net Profit | $-46.6M |
| Gross Margin | 68.5% |
| Operating Margin | -5.1% |
| Report Period | Q4 2025 |
Revenue Breakdown
BIOMARIN PHARMACEUTICAL INC Q4 2025 revenue of $874.6M breaks down across 9 segments, led by VOXZOGO at $273.4M (31.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| VOXZOGO | $273.4M | 31.3% |
| VIMIZIM | $205.5M | 23.5% |
| PALYNZIQ | $125.3M | 14.3% |
| NAGLAZYME | $120.2M | 13.7% |
| Other | $49.4M | 5.6% |
| ALDURAZYME | $49.4M | 5.6% |
| KUVAN | $23.3M | 2.7% |
| Royalty And Other | $15.2M | 1.7% |
| ROCTAVIAN | $12.8M | 1.5% |
BIOMARIN PHARMACEUTICAL INC Revenue by Segment — Quarterly Trend
BIOMARIN PHARMACEUTICAL INC revenue by segment across the last 4 reported quarters, showing how each business line (such as VOXZOGO and VIMIZIM) has evolved quarter over quarter.
| Segment | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| VOXZOGO | $273.4M | $218.4M | $221.4M | $213.8M |
| VIMIZIM | $205.5M | $182.8M | $215.4M | $188.3M |
| PALYNZIQ | $125.3M | $108.8M | $105.9M | $93.3M |
| NAGLAZYME | $120.2M | $122.0M | $128.9M | $114.3M |
| Other | $49.4M | — | — | — |
BIOMARIN PHARMACEUTICAL INC Annual Revenue by Year
BIOMARIN PHARMACEUTICAL INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.2B). Click any linked year to see what changed vs the prior 10-K.
BIOMARIN PHARMACEUTICAL INC Quarterly Revenue & Net Profit History
BIOMARIN PHARMACEUTICAL INC quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $874.6M | +17.0% | $-46.6M | -5.3% |
| Q3 2025 | $776.1M | +4.1% | $-30.7M | -4.0% |
| Q2 2025 | $825.4M | +15.9% | $240.5M | 29.1% |
| Q1 2025 | $745.1M | +14.8% | $185.7M | 24.9% |
| Q4 2024 | $747.3M | +15.6% | $124.9M | 16.7% |
| Q3 2024 | $745.7M | +28.3% | $106.1M | 14.2% |
| Q2 2024 | $712.0M | +19.6% | $107.2M | 15.1% |
| Q1 2024 | $648.8M | +8.8% | $88.7M | 13.7% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $648.8M | $712.0M | $745.7M | $747.3M | $745.1M | $825.4M | $776.1M | $874.6M |
| 同比增长 | 8.8% | 19.6% | 28.3% | 15.6% | 14.8% | 15.9% | 4.1% | 17.0% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $6.87B | $7.07B | $6.85B | $6.99B | $7.15B | $7.46B | $7.61B | $7.59B |
| 总负债 | $1.80B | $1.78B | $1.44B | $1.33B | $1.35B | $1.43B | $1.56B | $1.51B |
| 股东权益 | $5.07B | $5.29B | $5.41B | $5.66B | $5.79B | $6.03B | $6.06B | $6.09B |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $47.0M | $118.8M | $221.5M | $185.6M | $174.4M | $185.3M | $368.7M | $99.6M |